Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

1. A compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:

wherein:

T is selected from the group consisting of CHO, COR 8 , and C(OH)R 1 R 2 ;

R 1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, CF 3 , alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; R 3 is selected from the group consisting of hydrogen, lower alkyl and substituted lower alkyl;

R 4 is selected from the group consisting of(CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), and (F) n cycloalkyl;

n=1 –3;

R 5 is selected from the group consisting of hydrogen, halogen, CF 3 , diene fused to Y when Y═C, and substituted diene fused to Y when Y═C;

W, Y and Z are independently selected from the group consisting of C, CR 6 and N with the proviso that at least one of W or Y or Z must be C;

R 6 is selected from the group consisting of hydrogen, halogen, lower alkyl, and substituted lower alkyl;

X is selected from the group consisting of O, S, SO 2 , and NR 7 ;

R 7 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl; and

R 8 is selected from the group consisting of lower alkyl, CF 3 , phenyl, and substituted phenyl;

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.

2. The compound according to claim 1 , wherein R 5 is halogen.

3. The compound according to claim 2 , wherein R 5 is chlorine, bromine, or fluorine.

4. The compound according to claim 1 , wherein R 1 and R 2 are each hydrogen.

5. The compound according to claim 1 , wherein W is C and Z is CR 6 .

6. The compound according to claim 1 , wherein X is S, and W, Y and Z are independently selected from C or CR 6 , provided that one of W, Y or Z is C.

7. The compound according to claim 1 , wherein R 4 is selected from the group consisting of (CF 3 ) n loweralkyl, (CF 3 ) n (substitutedloweralkyl), (CF 3 ) n loweralkylphenyl, and (CF 3 ) n loweralkyl(substitutedphenyl) of S-stereochemistry.

8. The compound according to claim 1 , wherein X is S, W is C, Y is CH, Z is CH, R 5 is chlorine, R 4 is CF 3 CH 2 CHCH 3 , R 3 , R 1 and R 2 are each hydrogen, which has 1S, 2R stereochemistry.

9. The compound according to claim 1 , wherein X is S, W is C, Y is CH, Z is CH, R 5 is chlorine, R 4 is CF 3 CHCF 3 , R 3 , R 1 and R 2 are each hydrogen, which has 1S stereochemistry.

10. The compound according to claim 1 , wherein W is N and X is NR 7 .

11. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

5-Chloro-N-[(1S, 2R)-4,4,4-trifluoro-1-(hydroxymethyl)-2-methylbutyl]thiophene-2-sulfonamide;

5-Chloro-N-[(1S, 2R)-2-ethyl-4,4,4-trifluoro-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;

5′-Chloro-N-[(1S, 2R)-2-ethyl, 4,4,4-trifluoro-1-(1-hydroxyethyl)butyl]thiophene-2-sulfonamide;

5′-Chloro-N-[3,3,3-trifluoro-2-(trifluoromethyl)-1-hydroxymethyl)propyl]thiophene-2′-sulfonamide;

5′-Chloro-N-[3,3,3-trifluoro-2-(trifluoromethyl)-1-S-(hydroxymethyl)propyl]thiophene-2′-sulfonamide;

5-Chloro-N-[(1R, 2S)-2-ethyl-4,4,4-trifluoro-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;

5-Chloro-N-[4,4,4-trifluoro-1-(hydroxymethyl)butyl]thiophene-2-sulfonamide;

5-Chloro-N-{(1S, 2R)-4,4,4-trifluoro-1-[(1S)-1-hydroxyethyl]-2-methylbutyl}thiophene-2sulfonamide;

5-Chloro-N-{(1S, 2R)-4,4,4-trifluoro-1-[(1R)-1-hydroxyethyl]-2-methylbutyl}thiophene-2-sulfonamide;

5-Chloro-N-[(1S, 2S)-4,4,4-trifluoro-1-(hydroxymethyl)-2-methylbutyl]thiophene-2sulfonamide;

(2S, 3S)-2-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-amido-5,5,5-trifluoro-3-ethyl-pentan-1-ol;

(2S, 3R)-2-(5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl)-amido-5,5,5-trifluoro-3-phenyl-pentan-1-ol;

5-Chloro-N-[1-(4,4-difluorocyclohexyl)-2hydroxyethyl]thiophene-2-sulfonamide;

5-Chloro-N-[1-(6,6-difluorobicyclo[3.1.0]hex-3-yl)-2-hydroxyethyl]thiophene2-sulfonamide;

5-Chloro-N-[(1S, 2R)-4,4,4-trifluoro-1-formyl-2-methylbutyl]thiophene-2sulfonamide;

N-[(1S, 2R)-1Acetyl-4,4,4-trifluoro-2methylbutyl]-5-chlorothiophene-2-sulfonamide;

5-Chloro-N-[(1S, 2R)-4,4,4-trifluoro-1-(1-hydroxy-1-methylethyl)2-sulfonamide;

4-Bromo-5-chloro-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

4-Bromo-5-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Chloro 4-fluoro-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Bromo-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Fluoro-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Bromo-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Fluoro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(tifluoromethyl)propyl]thiophene-2-sulfonamide;

5-Chloro-N-[4,4,4-trifluoro-1-(hydroxymethyl)-2-(2,2,2-trifluoroethyl)butyl]thiophene-2sulfonamide;

5-Chloro-N-[(1S)-(4,4,4-trifluoro-1-(hydroxymethyl)-2-(2,2 2-trifluoroethyl)butyl]thiophene-2-sulfonamide;

4,5-Dichloro-N-[3,3,3-trifloro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

N-[(1S)-3,3,3-Trifluoro-1(hydroxymethyl)-2(trifluoromethyl)propy]thiophene-3-sulfonamide;

2,5-Dichloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-3-sulfonamide;

N-[(1S)-3,3,3-Trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

4,5-Dichloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

Thiophene-2-sulfonic acid (3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-amide;

Thiophene-3-sulfonic acid (3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-amide;

2-5-Dichloro-Thiophene-3-sulfonic acid (3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-amide;

4,5-Dibromo-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

3-Bromo-5-chloro-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

4-Bromo-2,5-dichloro-N-[3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

Benzo[b]thiophene-2-sulfonic acid (3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl)-amide;

5-Chloro-(3,3,3-trifluoro-1-hydroxymethyl-propyl)-thiophene-2-sulfonamide; and

5-Chloro-N-[(1S)-3,3,3-trifluoro-1-[(1R)-1-hydroxyethyl]-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide;

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.

12. The compound according to claim 1 , which is 5-chloro-N-[(1S)-(4,4,4-trifluoro-1-(hydroxymethyl)-2-(2,2,2-trifluoroethyl)butyl)]thiophene-2-sulfonamide; or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.

13. The compound according to claim 1 , wherein X is O, and W, Y and Z are independently selected from C and CR 6 , provided that one of W, Y or Z is C.

14. The compound according to claim 13 , wherein R 5 is halogen, R 4 is selected from the group consisting of (CF 3 ) n loweralkyl, (CF 3 ) n (substitutedloweralkyl), (CF 3 ) n loweralkylphenyl, (CF 3 ) n loweralkyl(substitutedphenyl) of S-stereochemistry, and R 3 , R 1 and R 2 are all H.

15. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 , and R 3 are H, and R 4 is (F) n cycloalkyl.

16. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 , and R 3 are H, and R 4 is (CF 3 ) n alkyl.

17. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 is CH 3 , R 2 is H, R 3 is H, and R 4 is (CF 3 ) n alkyl.

18. The compound according to claim 1 , wherein T is CHO, R 3 is H, and R 4 is (CF3) n alkyl.

19. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 and R 3 are H, and R 4 is (CF 3 ) 2 CH of S-stereochemistry.

20. The compound according to claim 1 , wherein T is CHO, R 3 , is H, and R 4 is CH(CH 3 )CH 2 CF 3 of S-stereochemistry.

21. The compound according to claim 1 , wherein T is C(O)R 8 , R 3 is H, R 4 is CH(CH 3 )CH 2 CF 3 of S-stereochemistry, and R 8 is CH 3 .

22. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 and R 3 are H, and R 4 is CH(CH 2 CF 3 ) 2 of S-stereochemistry.

23. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 and R 3 are H, and R 4 is CH(CH 3 )CH 2 CF 3 of S-stereochemistry.

24. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 is CH 3 , R 2 and R 3 are H, and R 4 is CH(CF 3 ) 2 of S-stereochemistry.

25. The compound according to claim 1 , wherein T is C(OH)R 1 R 2 , R 1 , R 2 and R 3 are H, and R 4 is (F) n cycloalkyl.

26. The compound according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of salts of organic acids, salts of inorganic acids, salts of bases, and mixtures thereof.

27. The compound according to claim 26 , wherein the salts of organic and inorganic acids are selected from the group consisting of acetic acid, lactic acid, citric acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malonic acid, mandelic acid, malic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, toluenesulfonic acid, and mixtures thereof.

28. The compound according to claim 26 , wherein the salts of bases are selected from the group consisting of sodium hydroxide, lithium hydroxide and potassium hydroxide, and mixtures thereof.

29. A pharmaceutical composition comprising a compound according to claim 1 and a physiologically compatible carrier.

30. A pharmaceutical composition comprising a prodrug according to claim 1 and a physiologically compatible carrier.